Cartalax

Cartalax
Identifiers
	IUPAC name (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid;
PubChem CID	87815447;
ChemSpider	16568512;
ChEBI	CHEBI:158137;
Chemical and physical data
Formula	C12H19N3O8
Molar mass	333.297 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N;
	InChI InChI=1S/C12H19N3O8/c1-5(13)10(20)14-6(2-3-8(16)17)11(21)15-7(12(22)23)4-9(18)19/h5-7H,2-4,13H2,1H3,(H,14,20)(H,15,21)(H,16,17)(H,18,19)(H,22,23)/t5-,6-,7-/m0/s1; Key:KXEVYGKATAMXJJ-ACZMJKKPSA-N;

Cartalax (Ala-Glu-Asp, T-31, AED) is a tripeptide derivative developed in Russia. It has anti-aging effects in vitro and in animal models, and has been sold in Russian-speaking countries as well as more broadly over the internet as a supposed treatment for conditions such as arthritis, though only limited studies in humans have been published.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

PubChem CID

87815447

ChemSpider

16568512

ChEBI

CHEBI:158137

FormulaC₁₂H₁₉N₃O₈

Quick facts Identifiers, PubChem CID ...

Close

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Cartalax

See also

References

Related Articles

Identifiers

IUPAC name (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid
PubChem CID	87815447
ChemSpider	16568512
ChEBI	CHEBI:158137
Chemical and physical data
Formula	C₁₂H₁₉N₃O₈
Molar mass	333.297 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N
InChI InChI=1S/C12H19N3O8/c1-5(13)10(20)14-6(2-3-8(16)17)11(21)15-7(12(22)23)4-9(18)19/h5-7H,2-4,13H2,1H3,(H,14,20)(H,15,21)(H,16,17)(H,18,19)(H,22,23)/t5-,6-,7-/m0/s1 Key:KXEVYGKATAMXJJ-ACZMJKKPSA-N